> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Class-wide Label Warning for Testosterone
- URL: https://www.fdaweb.com/class-wide-label-warning-for-testosterone/
- Published: 2016-10-25T12:00:00.000Z
- Updated: 2026-09-14T21:42:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137169

FDA has approved a class-wide labeling change for all prescription testosterone products, adding a new Warning and updating the Abuse and Dependence section to include new safety information from published literature and case reports regarding the risks associated with abuse and dependence of testosterone and other anabolic androgenic steroids (AAS). “Abuse of testosterone, usually at doses higher than those typically prescribed and usually in conjunction with other AAS, is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system,” an FDA [safety alert](http://www.fda.gov/Drugs/DrugSafety/ucm526206.htm?ref=fdaweb.com) says. “Reported serious adverse outcomes include heart attack, heart failure, stroke, depression, hostility, aggression, liver toxicity, and male infertility. Individuals abusing high doses of testosterone have also reported withdrawal symptoms, such as depression, fatigue, irritability, loss of appetite, decreased libido, and insomnia.”